ArticleJournal of personalized medicine2015
Common genetic risk for melanoma encourages preventive behavior change.
Article in Journal of personalized medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Psychosocial and behavioral outcomes of genomic testing in cancer: a systematic review.European journal of human genetics : EJHG · 2019Pooled it
- Prospective changes in primary care patients' family communication after skin cancer genetic test offer.PEC innovation · 2025Article
- COVID-19, Genetics, and Risk: Content Analysis of Facebook Posts Early in the Coronavirus Pandemic.Health communication · 2023Article
- Maturing pharmacogenomic factors deliver improvements and cost efficiencies.Cambridge prisms. Precision medicine · 2023Review
- Combination of Optical Biopsy with Patient Data for Improvement of Skin Tumor Identification.Diagnostics (Basel, Switzerland) · 2022Article
- Priority of Risk (But Not Perceived Magnitude of Risk) Predicts Improved Sun-Protection Behavior Following Genetic Counseling for Familial Melanoma.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2021Article
- Pharmacogenomic (PGx) Counseling: Exploring Participant Questions about PGx Test Results.Journal of personalized medicine · 2020Article
- The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer.BMC cancer · 2018Article
- Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.Translational behavioral medicine · 2018Article
- Precision Military Medicine: Conducting a multi-site clinical utility study of genomic and lifestyle risk factors in the United States Air Force.NPJ genomic medicine · 2017Article
- Challenges in Translating GWAS Results to Clinical Care.International journal of molecular sciences · 2016Article
- An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance.Thrombosis and haemostasis · 2016Observational
- Toward clinical genomics in everyday medicine: perspectives and recommendations.Expert review of molecular diagnostics · 2016Article
- Expression of miR-203 is decreased and associated with the prognosis of melanoma patients.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is currently great interest in using genetic risk estimates for common disease in personalized healthcare. Here we assess melanoma risk-related preventive behavioral change in the context of the Coriell Personalized Medicine Collaborative (CPMC). As part of on-going reporting activities within the project, participants received a personalized risk assessment including information related to their own self-reported family history of melanoma and a genetic risk variant showing a moderate effect size (1.7, 3.0 respectively for heterozygous and homozygous individuals). Participants who opted to view their report were sent an optional outcome survey assessing risk perception and behavioral change in the months that followed. Participants that report family history risk, genetic risk, or both risk factors for melanoma were significantly more likely to increase skin cancer preventive behaviors when compared to participants with neither risk factor (ORs = 2.04, 2.79, 4.06 and p-values = 0.02, 2.86 × 10-5, 4.67 × 10-5, respectively), and we found the relationship between risk information and behavior to be partially mediated by anxiety. Genomic risk assessments appear to encourage positive behavioral change in a manner that is complementary to family history risk information and therefore may represent a useful addition to standard of care for melanoma prevention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.